New CEO Kare Schultz is steering Teva Pharmaceutical Industries Limited (NYSE:TEVA) back into the good graces of investors, as the recovering Israeli pharma giant has stirred up shares on a just under 7% rise today. Cantor Louise Chen may be staying on the sidelines, but he acknowledges restructuring changes could be exactly what this biotech player needs to loosen its debt shackles.
Teva Pharmaceutical Industries Limited (TEVA) Restructuring Has This Sidelined Analyst Feeling More Positive
